Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
17.7M
-
Number of holders
-
13
-
Total 13F shares, excl. options
-
422K
-
Shares change
-
+203K
-
Total reported value, excl. options
-
$479K
-
Value change
-
+$246K
-
Number of buys
-
9
-
Number of sells
-
-4
-
Price
-
$1.17
Significant Holders of Kairos Pharma, LTD. - Common Stock, par value $0.001 per share (KAPA) as of Q3 2025
15 filings reported holding KAPA - Kairos Pharma, LTD. - Common Stock, par value $0.001 per share as of Q3 2025.
Kairos Pharma, LTD. - Common Stock, par value $0.001 per share (KAPA) has 13 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 422K shares
of 17.7M outstanding shares and own 2.38% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (132K shares), GEODE CAPITAL MANAGEMENT, LLC (65.8K shares), TWO SIGMA INVESTMENTS, LP (45.8K shares), SevenBridge Financial Group, LLC (44.3K shares), Aptus Capital Advisors, LLC (44.3K shares), TWO SIGMA SECURITIES, LLC (24.9K shares), STATE STREET CORP (24.1K shares), Quadrature Capital Ltd (14.9K shares), XTX Topco Ltd (12.4K shares), and UBS Group AG (5.98K shares).
This table shows the top 13 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.